The read at a glance
Computed from the FY2026 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 0.58 — distress zone — historically elevated failure riskWatch
- Earnings quality 100/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2026, as MCKESSON CORP reports it. History and quarterly detail are in the app.
- North American Pharmaceutical$336.7B
- Oncology & Multispecialty$48.4B
- Medical-Surgical Solutions$11.5B
- Prescription Technology Solutions$5.8B
Leadership changes
From MCKESSON CORP's own filings, the day they're filed.
- Kenny K. Cheung · President · appointmenteff. 2026-05-29
- Britt J. Vitalone · Chief Financial Officer · departureeff. 2026-03-03
- Deborah Dunsire · director · appointmenteff. 2024-06-03
Latest filings
- DEF 14A · Annual proxy (pay & governance)2026-06-12
- 8-K · Company announcement2026-06-12
- 10-K · Annual report2026-05-08
- 8-K · Company announcement2026-05-07
- 8-K · Company announcement2026-04-28
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about MCKESSON CORP, every answer cited🔒
- The Intelligence Brief — added when MCKESSON CORP's brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.